{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:30:28Z","timestamp":1779910228183,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"DOI":"10.7759\/cureus.102031","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:25:46Z","timestamp":1769055946000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis"],"prefix":"10.7759","author":[{"given":"Tyler","family":"Krall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kelbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chrisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser L","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021, 10:2235. 10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc AM","year":"2021","unstructured":"Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021, 14:7-16. 10.25122\/jml-2020-0145","journal-title":"J Med Life"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: Classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir MK","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized myasthenia gravis: Classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018, 36:253-60. 10.1016\/j.ncl.2018.01.002","journal-title":"Neurol Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282X-ANP-2022-S105","article-title":"Myasthenia gravis in clinical practice","volume":"80","author":"Estephan EP","year":"2022","unstructured":"Estephan EP, Baima JP, Zambon AA. Myasthenia gravis in clinical practice. Arq Neuropsiquiatr. 2022, 80:257-65. 10.1590\/0004-282X-ANP-2022-S105","journal-title":"Arq Neuropsiquiatr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor B","year":"2023","unstructured":"Claytor B, Cho SM, Li Y. Myasthenic crisis. Muscle Nerve. 2023, 68:8-19. 10.1002\/mus.27832","journal-title":"Muscle Nerve"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.6.517","article-title":"Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"30","author":"Lien PW","year":"2024","unstructured":"Lien PW, Joshi M, Tice JA, et al.. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. J Manag Care Spec Pharm. 2024, 30:517-27. 10.18553\/jmcp.2024.30.6.517","journal-title":"J Manag Care Spec Pharm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208162","article-title":"Cost-effectiveness analysis of efgartigimod versus chronic intravenous immunoglobulin (IVIg) for treatment of acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG) in Canada (P4-11.003)","volume":"102","author":"Siddiqi Z","year":"2024","unstructured":"Siddiqi Z, Genge A, Qi C, Zhou A, Kaprielian R, Locklin J, Garcia D. Cost-effectiveness analysis of efgartigimod versus chronic intravenous immunoglobulin (IVIg) for treatment of acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG) in Canada (P4-11.003). Neurology. 2024, 102:6900. 10.1212\/WNL.0000000000208162","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11733-y","article-title":"Myasthenia gravis, respiratory function, and respiratory tract disease","volume":"270","author":"Gilhus NE","year":"2023","unstructured":"Gilhus NE. Myasthenia gravis, respiratory function, and respiratory tract disease. J Neurol. 2023, 270:3329-40. 10.1007\/s00415-023-11733-y","journal-title":"J Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01181-3","article-title":"Antibody therapies in autoimmune neuromuscular junction disorders: Approach to myasthenic crisis and chronic management","volume":"19","author":"Vanoli F","year":"2022","unstructured":"Vanoli F, Mantegazza R. Antibody therapies in autoimmune neuromuscular junction disorders: Approach to myasthenic crisis and chronic management. Neurotherapeutics. 2022, 19:897-910. 10.1007\/s13311-022-01181-3","journal-title":"Neurotherapeutics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2296126","article-title":"An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis","volume":"23","author":"Matic A","year":"2023","unstructured":"Matic A, Alfaidi N, Bril V. An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis. Expert Opin Biol Ther. 2023, 23:1163-71. 10.1080\/14712598.2023.2296126","journal-title":"Expert Opin Biol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01059-8","article-title":"Myasthenia gravis treatment: From old drugs to innovative therapies with a glimpse into the future","volume":"38","author":"Crisafulli S","year":"2024","unstructured":"Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifir\u00f2 G, De Luca A. Myasthenia gravis treatment: From old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 2024, 38:15-32. 10.1007\/s40263-023-01059-8","journal-title":"CNS Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2184257","article-title":"Biological therapies for myasthenia gravis","volume":"23","author":"Uzawa A","year":"2023","unstructured":"Uzawa A, Utsugisawa K. Biological therapies for myasthenia gravis. Expert Opin Biol Ther. 2023, 23:253-60. 10.1080\/14712598.2023.2184257","journal-title":"Expert Opin Biol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11617-1","article-title":"Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"270","author":"Vu T","year":"2023","unstructured":"Vu T, Ortiz S, Katsuno M, et al.. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol. 2023, 270:3129-37. 10.1007\/s00415-023-11617-1","journal-title":"J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomized, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril V","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J, et al.. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomized, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023, 22:383-94. 10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomized, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF","year":"2021","unstructured":"Howard JF, Bril V, Vu T, et al.. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomized, placebo-controlled, phase 3 trial. Lancet Neurol. 2021, 20:526-36. 10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51121","article-title":"Consistent improvement with eculizumab across muscle groups in myasthenia gravis","volume":"7","author":"Mantegazza R","year":"2020","unstructured":"Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol. 2020, 7:1327-39. 10.1002\/acn3.51121","journal-title":"Ann Clin Transl Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu T","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, et al.. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022, 1:EVIDoa2100066. 10.1056\/EVIDoa2100066","journal-title":"NEJM Evid"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard JF Jr","year":"2020","unstructured":"Howard JF Jr, Nowak RJ, Wolfe GI, et al.. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020, 77:1-11. 10.1001\/jamaneurol.2019.5125","journal-title":"JAMA Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris PA","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009, 42:377-81. 10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe GI","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999, 52:1487-9. 10.1212\/wnl.52.7.1487","journal-title":"Neurology"},{"key":"ref21","unstructured":"R Core Team. The R Project for Statistical Computing. (2023). Accessed. December 7, 2025: https:\/\/www.R-project.org."},{"key":"ref22","unstructured":"Posit Team. RStudio: Integrated Development Environment for R. (2025). Accessed: December 7, 2025: http:\/\/www.posit.co\/."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod alfa in generalised myasthenia gravis: A profile of its use","volume":"37","author":"Heo YA","year":"2023","unstructured":"Heo YA. Efgartigimod alfa in generalised myasthenia gravis: A profile of its use. CNS Drugs. 2023, 37:467-73. 10.1007\/s40263-023-01000-z","journal-title":"CNS Drugs"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28334","article-title":"Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: Clinical experience at a single center","volume":"71","author":"Silvestri NJ","year":"2025","unstructured":"Silvestri NJ. Individualized dosing of efgartigimod in patients with generalized myasthenia gravis: Clinical experience at a single center. Muscle Nerve. 2025, 71:422-8. 10.1002\/mus.28334","journal-title":"Muscle Nerve"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard JF Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, et al.. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019, 92:e2661-73. 10.1212\/WNL.0000000000007600","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16189","article-title":"Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center","volume":"31","author":"Frangiamore R","year":"2024","unstructured":"Frangiamore R, Rinaldi E, Vanoli F, et al.. Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center. Eur J Neurol. 2024, 31:e16189. 10.1111\/ene.16189","journal-title":"Eur J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334086","article-title":"Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience","volume":"96","author":"Moniz Dion\u00edsio J","year":"2025","unstructured":"Moniz Dion\u00edsio J, Ambrose P, Burke G, et al.. Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience. J Neurol Neurosurg Psychiatry. 2025, 96:322-8. 10.1136\/jnnp-2024-334086","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard JF","year":"2023","unstructured":"Howard JF, Bresch S, Genge A, et al.. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023, 22:395-406. 10.1016\/S1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: A systematic review","volume":"38","author":"Landfeldt E","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochm\u00fcller H. Economic costs of myasthenia gravis: A systematic review. Pharmacoeconomics. 2020, 38:715-28. 10.1007\/s40273-020-00912-8","journal-title":"Pharmacoeconomics"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02101-9","article-title":"Efgartigimod: A review in generalised myasthenia gravis","volume":"84","author":"Blair HA","year":"2024","unstructured":"Blair HA. Efgartigimod: A review in generalised myasthenia gravis. Drugs. 2024, 84:1463-74. 10.1007\/s40265-024-02101-9","journal-title":"Drugs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/438252-real-world-outcomes-of-efgartigimod-in-adult-myasthenia-gravis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:25:47Z","timestamp":1769055947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/438252-real-world-outcomes-of-efgartigimod-in-adult-myasthenia-gravis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.102031","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}